PP2A Cancerous-IN-1

Cat. No.:	HY-139296
CAS No.:	1403933-79-8
Molecular Formula:	$C_{30}H_{24}N_4O_3$
Molecular Weight:	488.54
Target:	Akt
Pathway:	PI3K/Akt/mTOR
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	PP2A Cancerous-IN-1 is a strong and potent CIP2A (Cancerous inhibitor of PP2A) and p-Akt inhibitor. PP2A Cancerous-IN-1 shows the most potent antiproliferative activities[1].
IC_{50} & Target	pAKT

In Vitro

PP2A Cancerous-IN-1 (2.5 and 5 μM; 24 hours; SK-Hep-1 cells) reduces CIP2A expression and cell viability with a dose dependent manner and is more potent in its action than erlotinib[1].

PP2A Cancerous-IN-1 (5 μM; 24 hours; SK-Hep-1 cells) induces cell apoptosis[1].

PP2A Cancerous-IN-1 shows CIP2A inhibitory activity, reduces p-Akt level, induces PARP cleavage. PP2A Cancerous-IN-1 exhibits high potency with low IC50 values of 2.8 μM against HCC cells[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay[1]

Cell Line:	SK-Hep-1 cells
Concentration:	2.5 and 5 μM
Incubation Time:	24 hours
Result:	Reduced cell viability with a dose dependent manner.

Western Blot Analysis[1]

Cell Line:	SK-Hep-1 cells
Concentration:	2.5 and 5 μM
Incubation Time:	24 hours
Result:	Reduced CIP2A expression.

Apoptosis Analysis[1]

Cell Line:	SK-Hep-1 cells

Concentration:	2.5 and 5 μM
Incubation Time:	24 hours
Result:	Induced cell apoptosis.

REFERENCES

[1]. Chen KF, et al. Development of erlotinib derivatives as CIP2A-ablating agents independent of EGFR activity. Bioorg Med Chem. 2012;20(20):6144-6153.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA